Phaseline

Targets › GPER

GPER (G protein-coupled estrogen receptor 1): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2029.

G protein-coupled estrogen receptor that binds to 17-beta-estradiol (E2) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Stimulates cAMP production, calcium mobilization and tyrosine kinase Src inducing the release of heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal growth factor receptor (EGFR), activating…. (UniProt, Q99527)

Open in Phaseline: the race on GPER, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Linnaeus TherapeuticsLNS8801
G protein-coupled estrogen receptor (GPER) agonist
GPERPhase 2Melanoma (Skin Cancer); Solid Tumor, AdultFeb 2029

Conditions

Melanoma (Skin Cancer) (1) Solid Tumor, Adult (1)

Modalities

mixed (1)

Companies

Linnaeus Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.